340B Orphan Rx Discounts: HRSA Publishes List Of Non-Compliant Manufacturers
This article was originally published in The Pink Sheet Daily
Executive Summary
The Health Resources and Services Administration posts a list of 11 manufacturers it says are out of compliance with its requirements for providing 340B discounts on orphan drugs when they are used for non-orphan indications.
You may also be interested in...
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Khan Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.